Drug intelligence / Profile preview

MBRC-301

Development stage: Preclinical
Lead developer: MBrace Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MBRC-301 is an investigational antibody-drug conjugate (ADC) being developed by MBrace Therapeutics for the treatment of various solid tumors. Developed using a proprietary target discovery technology, MBRC-301 is designed to target a novel protein expressed on the surface of cancer cells. As of early 2024, the candidate is in the IND-enabling phase of development. While the specific molecular target, linker, and cytotoxic payload have not been publicly disclosed, the drug follows the classic ADC mechanism of selective delivery of a therapeutic agent to malignant cells to minimize systemic toxicity.

Beyond the preview

Go deeper on MBRC-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBRC-301.

Explore the full profile